In its first research misconduct finding of 2018, the HHS Office of Research Integrity (ORI) announced that Colleen Skau committed research misconduct when she was a postdoctoral fellow at the National Heart, Lung, and Blood Institute. In a 2/19/18 announcement posted on its website, ORI said Skau falsified, fabricated and otherwise skewed data in dozens […]

On January 17,  the U.S. Department of Health and Human Services and 15 other federal departments issued an interim final rule to delay the implementation of the revised Federal Policy for the Protection of Human Subjects (“Common Rule”) for six months, until July 19, 2018 to provide regulated entities additional time to make the necessary […]

Eleven figures in a 2016 paper were fabricated or falsified by a former NIH “research training awardee” who admitted to the misconduct and agreed to a three-year supervisory plan should she receive HHS research support in the future, according to a notice in the June 20 Federal Register. The HHS Office of Research Integrity (ORI) […]

At the link below is a proposed policy published in 2016, ICMJE today announced its requirements for data sharing in the near future (attached). Key points: As of 1 July 2018 manuscripts submitted to ICMJE journals that report the results of clinical trials must contain a data sharing statement Clinical trials that begin enrolling participants […]

The Food and Drug Administration (FDA) found numerous “objectionable conditions” during an inspection last summer of research conducted by Kang Zhang, professor of ophthalmology and chief of ophthalmic genetics at University of California San Diego, the agency said in a Jan. 5 “warning letter” recently posted online. “[W]e conclude that you did not adhere to […]

Andrew R. Cullinane, Ph.D., National Institutes of Health:  Based on Respondent’s admission, an assessment conducted by the National Institutes of Health (NIH), and analysis conducted by ORI in its oversight review, ORI found that Dr. Andrew R. Cullinane, former postdoctoral fellow, Medical Genetics Branch, National Human Genome Research Institute (NHGRI), NIH, engaged in research misconduct […]

Alexander Neumeister, M.D., former head of the molecular imaging program at New York University (NYU) School of Medicine, conducted psychiatric research without providing appropriate oversight, states a Feb. 6 warning letter issued by the Food and Drug Administration (FDA), which cited a host of problems uncovered in two protocols during an inspection from July 16-Aug. […]

The HHS Office of Research Integrity (ORI) has entered into a voluntary settlement agreement calling for the supervision of a researcher found to have committed misconduct at two different universities over a six-year period. In a May 24 notice on its website, ORI said Ricky Malhotra committed the misconduct while a research assistant professor in […]

A researcher has agreed to a five-year debarment for misconduct while another’s work, if involving Public Health Service (PHS) support, will be supervised for three years, according to the HHS Office of Research Integrity (ORI). The debarment was agreed to by John Pastorino, an associate professor in the Department of Molecular Biology at Rowan University […]

Patient deaths halted at least two pharmaceutical clinical trials in the last two months. The good news is, Robert Califf, M.D., who was confirmed by the Senate last week as commissioner of the Food and Drug Administration, has an opportunity to address this issue. In his new role, Dr. Califf is in a position to […]